Free Newsletter
Bickering may stall trial database
For years now, there's been talk of a centralized repository for all drug-testing data, one that's easily searchable and open to all comers--a sort of public library for the pharma-study set. If the databased were to become a reality, pre-approval studies, post-marketing studies and every clinical trial conducted anywhere in the world would be easily accessible and easily analyzed. Safety problems, or the lack thereof, would be easier to spot, or so the theory goes.
Now, as a September 30 deadline looms for legislative package of FDA funding and drug safety measures, House and Senate negotiators are duking it out over this very database. The House wants to specify exactly how the database would be configured; the Senate's version just calls for its establishment. Whether they'll agree in time to push the database into existence is anyone's guess.
- read the Los Angeles Times article
Related Articles:
PDUFA debate highlights drug safety issues. Report
Senate toughens drug safety supervision in PDUFA bill. Report
Waiting game continues for biogenerics. Report
Comments
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FiercePharma email newsletter for FREE!
Be the first to comment